Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28859793.
- Also identified by DOI 10.1016/j.jacc.2017.07.752.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.
Medical subject headings
- Anticholesteremic Agents
- Cardiovascular Diseases
- Cholesterol
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Muscle, Skeletal
- Muscular Diseases